var data={"title":"Acetylcysteine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetylcysteine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5566?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetylcysteine-drug-information\" class=\"drug drug_general\">see &quot;Acetylcysteine: Drug information&quot;</a> and <a href=\"topic.htm?path=acetylcysteine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetylcysteine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acetadote;</li>\n      <li>Cetylev</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acetylcysteine Injection;</li>\n      <li>Acetylcysteine Solution;</li>\n      <li>Mucomyst;</li>\n      <li>Parvolex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056251\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Acetaminophen</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mucolytic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48879029\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acetaminophen poisoning:</b> Limited data available in patients &lt;5 kg: Neonatal experience consists of several case reports and dosing utilized was based on suggested dosing for pediatric patients &gt;5 kg (Aw 1999; Bucaretchi 2014; de la Pintiere 2003; Isbister 2011; Nevin 2010; Walls 2007); the youngest patient reported to receive acetylcysteine for acetaminophen overdose was a neonate with GA 27 week, birthweight: 750 grams, and PNA 7 days at time of treatment (Brener 2013). Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal patient care.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Only the 72-hour oral and 21-hour IV regimens are FDA approved. Ideally, in patients with an acute acetaminophen ingestion, treatment should begin within 8 hours of ingestion or as soon as possible after ingestion. In patients with a suspected acute ingestion where the time of ingestion is unknown, the serum acetaminophen concentration is unobtainable or uninterpretable within 8 hours of ingestion, the patient presents &gt;8 hours after ingestion, or there is clinical evidence of toxicity, initiate treatment immediately and re-evaluate the need for acetylcysteine upon receipt of the results (if applicable). In patients who present following repeated supratherapeutic ingestions (RSTI) and treatment is deemed appropriate, acetylcysteine should be initiated immediately. Serum acetaminophen concentrations, liver function, and clinical status should be evaluated during and prior to the end of the treatment regimen to determine if treatment discontinuation is appropriate. Based on experience in older patients, patients who continue to experience symptoms of hepatotoxicity or elevated liver function tests at the conclusion of a 21-hour IV regimen, extending the treatment course may be appropriate; however, when and to which patients additional doses should be administered is unclear. Possible candidates for extended therapy include patients with a suspected massive overdose, concomitant ingestion of other substances, or patients with preexisting liver disease. In patients with persistently elevated acetaminophen concentrations, persistently elevated liver function tests, or an elevated INR, additional acetylcysteine administration should be considered. Typically, an additional &quot;third dose&quot; or &quot;third bag&quot; (IV: 100 mg/kg infused over 16 hours) is administered; however, this dose may be inadequate in some patients (Rumac 2012); neonatal experience describing administration of a &ldquo;third bag&rdquo; is lacking. Consultation with a poison control center or clinical toxicologist recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV (Acetadote): 21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Loading dose: 150 mg/kg infused over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Second dose: 50 mg/kg infused over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Third dose: 100 mg/kg infused over 16 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056243\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=acetylcysteine-drug-information\" class=\"drug drug_general\">see &quot;Acetylcysteine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acetaminophen poisoning:</b> Infants, Children, and Adolescents: Only the 72-hour oral and 21-hour IV regimens are FDA approved. Ideally, in patients with an acute acetaminophen ingestion, treatment should begin within 8 hours of ingestion or as soon as possible after ingestion. In patients with a suspected acute ingestion where the time of ingestion is unknown, the serum acetaminophen concentration is unobtainable or uninterpretable within 8 hours of ingestion, the patient presents &gt;8 hours after ingestion, or there is clinical evidence of toxicity, initiate treatment immediately and re-evaluate the need for acetylcysteine upon receipt of the results (if applicable). In patients who present following repeated supratherapeutic ingestions (RSTI) and treatment is deemed appropriate, acetylcysteine should be initiated immediately. Regardless of the treatment regimen selected, serum acetaminophen concentrations, liver function, and clinical status should be evaluated during and prior to the end of the treatment regimen to determine if treatment discontinuation is appropriate. In patients who continue to experience symptoms of hepatotoxicity or elevated liver function tests at the conclusion of a 72-hour oral or 21-hour IV regimen, extending the treatment course may be appropriate; however, when and to which patients additional doses should be administered is unclear. Possible candidates for extended therapy include patients with a suspected massive overdose, concomitant ingestion of other substances, or patients with preexisting liver disease. In patients with persistently elevated acetaminophen concentrations, persistently elevated liver function tests, or an elevated INR, additional acetylcysteine should be administered. Typically, an additional &quot;third dose&quot; or &quot;third bag&quot; (IV: 100 mg/kg [maximum dose: 10 g/dose] infused over 16 hours) is administered; however, this dose may be inadequate in some patients (Rumac 2012). Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Effervescent tablet (Cetylev) or solution for oral administration (using injectable/nebulizer formulation): There is no data for use of the OTC supplement tablets for acetaminophen poisoning. Dosing below is based on effervescent tablet (Cetylev) or a solution for oral administration that is prepared from the solution for oral inhalation: 72-hour regimen: Consists of 18 doses; total dose delivered: 1,330 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 140 mg/kg; maximum dose: 15 <b>g/</b>dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 70 mg/kg every 4 hours for 17 doses; maximum dose: 7.5 <b>g/</b>dose; <b>repeat</b> dose if emesis occurs within 1 hour of administration; <b>Note:</b> Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetylcysteine prior to the conclusion of a full 18-dose course of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (Acetadote): 21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Loading dose: 150 mg/kg infused over 60 minutes; maximum dose: 15 <b>g</b>/dose</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Second dose: 50 mg/kg infused over 4 hours; maximum dose: 5 <b>g</b>/dose</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Third dose: 100 mg/kg infused over 16 hours; maximum dose: 10 <b>g</b>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory conditions, adjuvant therapy: Note:</b> Patients should receive an aerosolized bronchodilator 10 to 15 minutes prior to acetylcysteine:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nebulized inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Face mask, mouth piece, tracheostomy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: 1 to 2 mL of 20% solution (may be further diluted with sodium chloride or sterile water for inhalation) or 2 to 4 mL of 10% solution (undiluted); administer 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children: 3 to 5 mL of 20% solution (may be further diluted with sodium chloride or sterile water for inhalation) or 6 to 10 mL of 10% solution (undiluted); administer 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 3 to 5 mL of 20% solution (may be further diluted with sodium chloride or sterile water for inhalation) or 6 to 10 mL of 10% solution (undiluted); administer 3 to 4 times daily; usual dosing range: 20% solution: 1 to 10 mL or 10% solution: 2 to 20 mL every 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Tent, croupette:</i> 10% or 20% solution: Dose must be individualized; dose is volume of solution necessary to maintain a very heavy mist in tent or croupette; in some cases, may require up to 300 mL solution/treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct instillation: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Endotracheal: 1 to 2 mL of 10% to 20% solution every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Percutaneous endotracheal catheter: 1 to 2 mL of 20% or 2 to 4 mL of 10% solution every 1 to 4 hours via syringe attached to catheter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic bronchogram:</b> Children and Adolescents: Nebulization or endotracheal: 1 to 2 mL of 20% solution or 2 to 4 mL of 10% solution administered 2 to 3 times prior to procedure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Distal intestinal obstruction syndrome (previously known as meconium ileus equivalent):</b> Limited data available; dosing regimens variable (polyethylene glycol has become more widely used for this indication):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;10 years: 30 mL of 10% solution diluted in 30 mL juice or soda 3 times/day for 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 10 years and Adolescents: 60 mL of 10% solution diluted in 60 mL juice or soda 3 times/day for 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Prior to treatment, administer a phosphosoda enema. A clear liquid diet should be used during the 24-hour acetylcysteine treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal enema: Children: Varying dosages; 100 to 300 mL of 4% to 6% solution 2 to 4 times daily; 50 mL of 20% solution 1 to 4 times daily and 5 to 30 mL of 10% to 20% solution 3 to 4 times daily have been used; rectal enemas appear to have less favorable results than oral administration (Mascarenhas 2003).<b> Note:</b> Higher concentrations (10% to 20%) appear to increase fluid in the bowel and lead to increased incidence of adverse effects (Perman 1975)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acetaminophen poisoning:</b> Only the 72-hour oral and 21-hour IV regimens are FDA approved. Ideally, in patients with an acute acetaminophen ingestion, treatment should begin within 8 hours of ingestion or as soon as possible after ingestion. In patients with a suspected acute ingestion where the time of ingestion is unknown, the concentration is unobtainable or uninterpretable within 8 hours of ingestion, the patient presents &gt;8 hours after ingestion, or there is clinical evidence of toxicity, initiate treatment immediately and re-evaluate the need for acetylcysteine upon receipt of the results (if applicable). In patients who present following RSTI and treatment is deemed appropriate, acetylcysteine should be initiated immediately. Regardless of the treatment regimen selected, serum acetaminophen concentrations, liver function, and clinical status should be evaluated during and prior to the end of the treatment regimen to determine if treatment discontinuation is appropriate. In patients who continue to experience symptoms of hepatotoxicity or elevated liver function tests at the conclusion of a 72-hour oral or 21-hour IV regimen, extending the treatment course may be appropriate; however, when and to which patients additional doses should be administered is unclear. Possible candidates for extended therapy include patients with a suspected massive overdose, concomitant ingestion of other substances, or patients with preexisting liver disease. In patients with persistently elevated acetaminophen concentrations, persistently elevated liver function tests, or an elevated INR, additional acetylcysteine should be administered. Typically, an additional &quot;third dose&quot; or &quot;third bag&quot; (IV: 100 mg/kg [maximum: 10 g] infused over 16 hours) is administered; however, this dose may be inadequate in some patients (Rumac 2012). Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (effervescent tablets [Cetylev]; solution for oral administration): 72-hour regimen: Consists of 18 doses; total dose delivered: 1,330 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &le;100 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 140 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: 70 mg/kg every 4 hours; repeat dose if emesis occurs within 1 hour of administration</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &gt;100 kg: Oral: Effervescent tablets (Cetylev): Limited information exists regarding the oral dosing requirements of patients &gt;100 kg. 72-hour regimen: Consists of 18 doses; total dose delivered: 142.5 g</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: 15 g</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: 7.5 g every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (Acetadote):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &le;100 kg: 21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: 150 mg/kg (maximum: 15 g) infused over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Second dose: 50 mg/kg (maximum: 5 g) infused over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Third dose: 100 mg/kg (maximum: 10 g) infused over 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &gt;100 kg: 21-hour regimen: Consists of 3 doses; total dose delivered: 30 <b>g</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: 15 <b>g</b> infused over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Second dose: 5 <b>g</b> infused over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Third dose: 10 <b>g</b> infused over 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory conditions; adjuvant therapy:</b> <b>Note:</b> Patients should receive an aerosolized bronchodilator 10 to 15 minutes prior to dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation, nebulization (face mask, mouth piece, tracheostomy): Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted: 3 to 5 mL of 20% solution or 6 to 10 mL of 10% solution until nebulized given 3 to 4 times daily; dosing range: 1 to 10 mL of 20% solution or 2 to 20 mL of 10% solution every 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation, nebulization (tent, croupette): Dose must be individualized; may require up to 300 mL solution/treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct instillation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Into tracheostomy: 1 to 2 mL of 10% to 20% solution every 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Through percutaneous intratracheal catheter: 1 to 2 mL of 20% or 2 to 4 mL of 10% solution every 1 to 4 hours via syringe attached to catheter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic bronchogram:</b> Nebulization or intratracheal: 1 to 2 mL of 20% solution or 2 to 4 mL of 10% solution administered 2 to 3 times prior to procedure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of radiocontrast-induced renal dysfunction:</b> Oral: 1,200 mg (every 12 hours) starting the day prior to the procedure and on the day of procedure for a total of 4 doses (ACT Investigators 2011). <b>Note:</b> No longer recommended for use prior to left ventricular angiography or percutaneous coronary intervention; instead adequate hydration is preferred (ACCF/AHA/SCAI [Levine 2011]; AHA/ACC [Amsterdam 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130142\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [preservative free]: 20% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acetadote: 20% [200 mg/mL] (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, for inhalation/oral: 10% [100 mg/mL] (10 mL, 30 mL); 20% [200 mg/mL] (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, for inhalation/oral [preservative free]: 10% [100 mg/mL] (4 mL, 10 mL, 30 mL); 20% [200 mg/mL] (4 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Effervescent, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cetylev: 500 mg, 2.5 g [contains edetate disodium; lemon mint flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130127\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes; excludes effervescent tablet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056255\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Differs based on use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen poisoning:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Effervescent tablets (Cetylev): Use within 2 hours of preparation. If the patient vomits within 1 hour of administration, repeat that dose. If the patient is persistently unable to retain the orally administered acetylcysteine, acetylcysteine may be administered by nasoduodenal tube.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution for oral administration: Administer as a 5% solution (see Preparation for Administration); use within 1 hour of preparation. If patient vomits within 1 hour of dose, readminister. <b>Note:</b> The unpleasant odor (sulfur-like) becomes less noticeable as treatment progresses. It is helpful to put the acetylcysteine on ice, in a cup with a cover, and drink through a straw; alternatively, administer via an NG tube.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention of contrast induced nephropathy: Adults: Using the 20% solution, each 1,200 mg dose should be diluted immediately prior to use in a minimum of 20 mL of a cola drink or other soft drink (or water if administered via NG tube); use within 1 hour of preparation (Massicotte 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Acetaminophen poisoning: IV (Acetadose):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Administer IV over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose: Administer IV over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Third dose: Administer IV over 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation solution: May be administered by nebulization either undiluted (both 10% and 20%) or diluted in NS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Inhalation solution may be given undiluted (10% to 20%) or diluted to 4% to 6% solution  and administer rectally (Mascarenhas 2003; Perman 1975)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130161\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Effervescent tablets (Cetylev): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. Following dissolution in water, the solution should be used within 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for inhalation/oral administration: Store unopened vials at room temperature; once opened, store under refrigeration and use within 96 hours. A color change may occur in opened vials (light purple) and does not affect the safety or efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection (Acetadote): Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Following reconstitution, solution is stable for 24 hours at room temperature. A color change may occur in opened vials (light pink or purple) and does not affect the safety or efficacy. Discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056254\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: Adjunctive therapy in patients with abnormal, viscid, or inspissated mucous secretions in conditions such as chronic bronchopulmonary diseases (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, primary amyloidosis of the lung); acute pulmonary diseases (pneumonia, bronchitis, tracheobronchitis); pulmonary complications of cystic fibrosis; tracheostomy care; pulmonary complications associated with surgery; use during anesthesia; post-traumatic chest conditions; atelectasis due to mucous obstruction; diagnostic bronchial studies (bronchograms, bronchospirometry, bronchial wedge catheterization (All indications: FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, Oral: Antidote for acetaminophen toxicity to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSTI) (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used orally and rectally to treat distal intestinal obstruction syndrome (previously known as &ldquo;meconium ileus or its equivalent&rdquo;)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130222\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acetylcysteine may be confused with acetylcholine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucomyst may be confused with Mucinex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130219\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema, flushing, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Rash, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Autoimmune disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis, rhinorrhea, rhonchi, throat tightness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, bronchospasm, chest tightness, cough, dizziness (Sandilands 2008), dyspnea (Sandilands 2008), hypotension, respiratory distress, stridor, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest tightness, hypotension (Bebarta 2010; Sandilands 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Rash (with or without fever), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal symptoms, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Angioedema (Bebarta 2010), tachycardia (Bebarta 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130149\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to acetylcysteine or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Effervescent tablet (Cetylev): There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130131\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Acute flushing and erythema have been reported; usually occurs within 30 to 60 minutes and may resolve spontaneously. Serious anaphylactoid reactions (some fatal) have also been reported and are more commonly associated with IV administration, but also occur with oral administration (Mroz 1997). When used for acetaminophen overdose, the incidence is reduced when the initial intravenous loading dose is administered over 60 minutes. The acetylcysteine infusion may be interrupted until the treatment of allergic symptoms is initiated; the infusion can then be carefully restarted. Treatment for anaphylactoid reactions should be immediately available. Conversely, patients with high acetaminophen concentrations (&gt;150 mg/L) may be at a reduced risk for anaphylactoid reactions (Pakravan 2008; Sandilands 2009; Waring 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: IV administration can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload in patients &le;40 kg and those requiring fluid restriction, decrease volume of diluent proportionally (see table in dosing section).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma/bronchospasm: Use caution in patients with asthma or history of bronchospasm; these patients may be at increased risk of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute acetaminophen overdose: Appropriate use: Acetylcysteine is indicated in patients with a serum acetaminophen concentration that indicates they are at &quot;possible&quot; risk or greater for hepatotoxicity when plotted on the Rumack-Matthew nomogram. There are several situations where the nomogram is of limited use. Serum acetaminophen concentrations obtained &lt;4 hours postingestion are not reliable, except to document the presence of acetaminophen (Seifert 2015). Patients presenting late may have undetectable serum concentrations, despite having received a toxic dose. The nomogram is less predictive of hepatic injury following an acute overdose with an extended release acetaminophen product. The nomogram also does not take into account patients who may be at higher risk of acetaminophen toxicity (eg, alcoholics, malnourished patients, concurrent use of CYP2E1 enzyme-inducing agents [eg, isoniazid]). Nevertheless, acetylcysteine should be administered to any patient with signs of hepatotoxicity, even if the serum acetaminophen concentration is low or undetectable. Patients who present &gt;24 hours after an acute ingestion or patients who present following an acute ingestion at an unknown time may be candidates for acetylcysteine therapy; consultation with a poison control center or clinical toxicologist is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Repeated supratherapeutic ingestion (RSTI) of acetaminophen: Appropriate use: The Rumack-Matthew nomogram is not designed to be used following RSTIs. In general, an accurate past medical history, including a comprehensive acetaminophen ingestion history, in conjunction with AST concentrations and serum acetaminophen concentrations, may give the clinician insight as to the patient's risk of acetaminophen toxicity. Some experts recommend that acetylcysteine be administered to any patient with &quot;higher than expected&quot; serum acetaminophen concentrations or serum acetaminophen concentration &gt;10 mcg/mL, even in the absence of hepatic injury; others recommend treatment for patients with laboratory evidence and/or signs and symptoms of hepatotoxicity (Hendrickson 2006; Jones 2000). Consultation with a poison control center or a clinical toxicologist is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effervescent tablets (Cetylev): Contains sodium; consider acetylcysteine treatment as a source of sodium in patients who may be sensitive to excess sodium intake (eg, heart failure, hypertension, renal impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral administration: Gastrointestinal hemorrhage: Oral administration of acetylcysteine may result in nausea and vomiting, which may exacerbate vomiting associated with acetaminophen overdose. Therefore, patients at risk of gastrointestinal hemorrhage (eg, esophageal varices, peptic ulcer) may experience an even higher risk of gastrointestinal hemorrhage during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhalation: Since increased bronchial secretions may develop after inhalation, percussion, postural drainage, and suctioning should follow. If bronchospasm occurs, administer a bronchodilator; discontinue acetylcysteine if bronchospasm progresses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298677\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130136\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13239&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130152\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Based on limited reports using acetylcysteine to treat acetaminophen overdose in pregnant women, acetylcysteine has been shown to cross the placenta and may provide protective concentrations in the fetus.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Acetylcysteine may be used to treat acetaminophen overdose in during pregnancy (Wilkes 2005). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056250\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen poisoning: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BUN, serum glucose, hemoglobin, hematocrit, and electrolytes. Assess patient for nausea, vomiting, and skin rash following oral administration. Reassess LFTs for possible hepatotoxicity every 4 to 6 hours. An early elevation in the INR may be related to acetylcysteine therapy (Schmidt 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute ingestion: Obtain the first acetaminophen concentration 4 hours postingestion (or as soon as possible thereafter); plot on the Rumack-Matthew nomogram. In patients who have ingested an extended release formulation of acetaminophen or have coingested an agent known to delay gastric emptying, obtain a repeat serum acetaminophen measurement 4 to 6 hours following the first measurement if the original concentration (taken at 4 to 8 hours postingestion) when plotted on the Rumack-Matthew nomogram indicated that treatment was not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130130\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen overdose: Acetylcysteine acts as a hepatoprotective agent by restoring hepatic glutathione, serving as a glutathione substitute, and enhancing the nontoxic sulfate conjugation of acetaminophen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mucolytic: Exerts mucolytic action through its free sulfhydryl group which opens up the disulfide bonds in the mucoproteins thus lowering mucous viscosity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130148\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Inhalation: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Inhalation: &gt;1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.47 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 66% to 87%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes extensive first pass metabolism to form cysteine and disulfides (N,N-diacetylcysteine and N-acetylcysteine); cysteine is further metabolized to form glutathione and other metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reduced acetylcysteine: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total acetylcysteine: Adults: 5.6 hours; Newborns: 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Effervescent tablets: Terminal half-life: 18.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral solution: 1 to 2 hours; Effervescent tablets: 1 to 3.5 hours (median: 2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (13% to 38%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130151\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetadote Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (30 mL): $258.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetylcysteine Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (10 mL): $12.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (10 mL): $14.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetylcysteine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (30 mL): $225.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, effervescent</b> (Cetylev Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g (20): $433.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $86.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130153\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ac-Lyte (PH);</li>\n      <li>ACC (AR, BG, CH, CR, CZ, DE, DO, GT, HN, HU, LB, LU, MX, NI, PA, RU, SA, SK, SV, ZA);</li>\n      <li>ACC 200 (AE, BH, EE, KW, QA);</li>\n      <li>ACC Long (QA);</li>\n      <li>Acemuc (EC);</li>\n      <li>Acemuk (AR, CL);</li>\n      <li>Acet (TW);</li>\n      <li>Acetadote (AU, NZ);</li>\n      <li>Acetein (KR);</li>\n      <li>Acetimax (PH);</li>\n      <li>Acetin (ID, MY);</li>\n      <li>Acetylcystein NM Pharma (SE);</li>\n      <li>Acetylcystein Tika (SE);</li>\n      <li>Acetyst (DE);</li>\n      <li>Actein (HK);</li>\n      <li>Aflux (CO, EC);</li>\n      <li>Aires (BR);</li>\n      <li>Bisolbruis (NL);</li>\n      <li>Brimodin (PE);</li>\n      <li>Bromuc (BR);</li>\n      <li>Bronchocil (BE);</li>\n      <li>Broncoflem (PH);</li>\n      <li>Broncolium (AR);</li>\n      <li>Brunac (JO);</li>\n      <li>Cetilan (PH);</li>\n      <li>Cilol (LK);</li>\n      <li>Cirocyst (LK);</li>\n      <li>Codotussyl (SG);</li>\n      <li>Cystaline (TH);</li>\n      <li>Dextein (PH);</li>\n      <li>Drenaflen (DO, EC);</li>\n      <li>Ecomucyl (CH);</li>\n      <li>Encore (TW);</li>\n      <li>Enumine NAC (TH);</li>\n      <li>Exflem (PH);</li>\n      <li>Exomuc (FR, LB, LU, VN);</li>\n      <li>Fabrol (AT, GR);</li>\n      <li>Flemex AC (TH);</li>\n      <li>Flemex-AC OD (TH);</li>\n      <li>Flucil (TH);</li>\n      <li>Fluidasa (CL, VN);</li>\n      <li>Fluidine (EC);</li>\n      <li>Fluimicil (CH, DE);</li>\n      <li>Fluimiquil (LU);</li>\n      <li>Fluimucil (AR, AT, BG, BR, CO, CZ, ES, FR, GR, HK, HU, ID, IT, LB, NL, PE, PL, PT, QA, RU, SA, SG, TH, TW, VN);</li>\n      <li>Fluimucil A (MY, PK);</li>\n      <li>Fluimukan (HR, SI);</li>\n      <li>Flumex (PH);</li>\n      <li>Flumil (ES);</li>\n      <li>Flumixol (CO);</li>\n      <li>Flutafin (TW);</li>\n      <li>Genac (FR);</li>\n      <li>Glotamuc (VN);</li>\n      <li>Granon (DK);</li>\n      <li>Hidonac (HK, ID, MY, PH, TH, TW);</li>\n      <li>Icystein (TW);</li>\n      <li>Ilube (GB);</li>\n      <li>L-Cimexyl (SG);</li>\n      <li>Lubrisec (AR);</li>\n      <li>Lysomucil (BE, CR, DO, GT, HN, LU, NI, PA, SV);</li>\n      <li>Lysox (BE, LU);</li>\n      <li>Madame Pearl's Mucolytic (HK);</li>\n      <li>Mentopin (MY, SG);</li>\n      <li>Mitux (VN);</li>\n      <li>Moktin (KR);</li>\n      <li>Muclear (TH);</li>\n      <li>Mucobene (AT);</li>\n      <li>Mucocar (PE);</li>\n      <li>Mucocystein (PH);</li>\n      <li>Mucofillin (JP);</li>\n      <li>Mucofluid (EE);</li>\n      <li>Mucolair (LU);</li>\n      <li>Mucolator (LU, MY);</li>\n      <li>Mucolitico (CL, CN);</li>\n      <li>Mucolysin (IS);</li>\n      <li>Mucolyte (LK);</li>\n      <li>Mucomist (BD);</li>\n      <li>Mucomyst (DK, FI, FR, GR, KR, LU, NO, SE);</li>\n      <li>Mucomystendo (FR);</li>\n      <li>Mucoserin (KR);</li>\n      <li>Mucosoft (BG);</li>\n      <li>Mucosten (KR);</li>\n      <li>Mucosys (IN);</li>\n      <li>Mucylin (ID);</li>\n      <li>Mufresin (PH);</li>\n      <li>Muterin (KR);</li>\n      <li>Muxatil (PY);</li>\n      <li>Mysoven (TH);</li>\n      <li>N-Acc (ID);</li>\n      <li>NAC (TR);</li>\n      <li>NAC-ratiopharm (LU);</li>\n      <li>Nacetyl (PH);</li>\n      <li>Parvolex (GB, IE, NZ, ZA);</li>\n      <li>Pectocil (ID);</li>\n      <li>Pectomucil (LU);</li>\n      <li>Pulmovital (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Reolin (IL);</li>\n      <li>Respar (ID);</li>\n      <li>Rinofluimucil (JO);</li>\n      <li>Rumicil (LU);</li>\n      <li>Sebron (KR);</li>\n      <li>Sensemoc (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Simucil (ID);</li>\n      <li>Simucin (TH);</li>\n      <li>Siran 200 (IL);</li>\n      <li>Siran Forte (ID);</li>\n      <li>Solmucol (CZ, HU, IT, LU, SG, SK);</li>\n      <li>Spatam (SG);</li>\n      <li>Sputopur (HU);</li>\n      <li>Stacytine (VN);</li>\n      <li>Stecin (KR);</li>\n      <li>Stenac (MY);</li>\n      <li>Systalin (BD);</li>\n      <li>Tancore (TW);</li>\n      <li>Tirocular (PT);</li>\n      <li>Toflux (AR);</li>\n      <li>Touxium Mucolyticum (LU);</li>\n      <li>Viscotin (BD);</li>\n      <li>Viskoferm (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acetadote (acetylcysteine) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acetylcysteine injection [prescribing information]. Lake Forest, IL: Akorn, Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). <i>Circulation</i>. 2011; 124(11):1250-1259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/21859972/pubmed\" target=\"_blank\" id=\"21859972\">21859972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;130(25):e433-e434]. <i>Circulation</i>. 2014;130(25):e344-e426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/25249585/pubmed\" target=\"_blank\" id=\"25249585\">25249585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. <i>Emerg Med J</i>. 2002;19(6):594-595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/12421803/pubmed\" target=\"_blank\" id=\"12421803\">12421803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aw MM, Dhawan A, Baker AJ, Mieli-Vergani G. Neonatal paracetamol poisoning. <i>Arch Dis Child Fetal Neonatal Ed</i>.1999;81(1):F78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/10744435/pubmed\" target=\"_blank\" id=\"10744435\">10744435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brener P, Ballardo M, Mariani G, Ceriani Cernadas JM. Medication error in an extremely low birth weight infant: paracetamol overdose. <i>Arch Argent Pediatr</i>. 2013;111(1):53-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/23381705/pubmed\" target=\"_blank\" id=\"23381705\">23381705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bucaretchi F, Fernandes CB, Branco MM, et al. Acute liver failure in a term neonate after repeated paracetamol administration. <i>Rev Paul Pediatr</i>. 2014;32(1):144-148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/24676202/pubmed\" target=\"_blank\" id=\"24676202\">24676202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cetylev (acetylcysteine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de la Pinti&eacute;re A, Beuch&eacute;e A, B&eacute;tr&eacute;mieux PE. Intravenous propacetamol overdose in a term newborn. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2003;88(4):F351-352.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/12819181/pubmed\" target=\"_blank\" id=\"12819181\">12819181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanly JG and Fitzgerald MX, &ldquo;Meconium Ileus Equivalent in Older Patients With Cystic Fibrosis,&rdquo; <i>Br Med J (Clin Res Ed)</i>, 1983, 286(6375):1411-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/6404483 /pubmed\" target=\"_blank\" id=\"6404483 \">6404483 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendrickson RG and Bizovi KE, &ldquo;Acetaminophen,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 8th edition, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York: The McGraw-Hill Companies, Inc, 2006, 523-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, Bucens IK, Whyte IM. Paracetamol overdose in a preterm neonate. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2001;85(1):F70-72<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/11420329/pubmed\" target=\"_blank\" id=\"11420329\">11420329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones AL, &ldquo;Mechanism of Action and Value of N-Acetylcysteine in the Treatment of Early and Late Acetaminophen Poisoning: A Critical Review,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36(4):277-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/9711192/pubmed\" target=\"_blank\" id=\"9711192\">9711192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones AL, &ldquo;Recent Advances in the Management of Late Paracetamol Poisoning,&rdquo; <i>Emerg Med</i>, 2000, 12(1):14-21.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i>. 2011; 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mascarenhas MR, &ldquo;Treatment of Gastrointestinal Problems in Cystic Fibrosis,&rdquo; <i>Curr Treat Options Gastroenterol</i>, 2003, 6(5):427-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/12954149 /pubmed\" target=\"_blank\" id=\"12954149 \">12954149 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massicotte A. Contrast medium-induced nephropathy: strategies for prevention. <i>Pharmacotherapy</i>. 2008;28(9):1140-1150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/18752385/pubmed\" target=\"_blank\" id=\"18752385\">18752385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mroz L, Benitez JG, and Krenzelok E, &ldquo;Angioedema With Oral Acetylcysteine,&rdquo; <i>Ann Emerg Med</i>, 1997, 30(2):240-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/9250658/pubmed\" target=\"_blank\" id=\"9250658\">9250658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nevin DG, Shung J. Intravenous paracetamol overdose in a preterm infant during anesthesia. <i>Paediatr Anaesth</i>. 2010;20(1):105-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/20078803/pubmed\" target=\"_blank\" id=\"20078803\">20078803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pakravan N, Waring WS, Sharma S, et al, &ldquo;Risk Factors and Mechanisms of Anaphylactoid Reactions to Acetylcysteine in Acetaminophen Overdose,&rdquo; <i>Clin Toxicol</i>, 2008, 46(8):697-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/18803085/pubmed\" target=\"_blank\" id=\"18803085\">18803085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perman J, Breslow L, Ingal D. Nonoperative treatment of meconium ileus equivalent. <i>Am J Dis Child</i>. 1975;129(10):1210-1211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/1190145 /pubmed\" target=\"_blank\" id=\"1190145 \">1190145 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rashid ST, Salman M, Myint F, et al, &quot;Prevention of Contrast-Induced Nephropathy in Vascular Patients Undergoing Angiography: A Randomized Controlled Trial of Intravenous N-Acetylcysteine,&quot; <i>J Vasc Surg</i>, 2004, 40(6):1136-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/15622367/pubmed\" target=\"_blank\" id=\"15622367\">15622367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. <i>Clin Toxicol (Phila)</i>. 2012;50(2):91-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/22320209/pubmed\" target=\"_blank\" id=\"22320209\">22320209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandilands EA and Bateman DN, &ldquo;Adverse Reactions Associated With Acetylcysteine,&rdquo; <i>Clin Toxicol (Phila)</i>, 2009, 47(2):81-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/19280424/pubmed\" target=\"_blank\" id=\"19280424\">19280424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt LE, Knudsen TT, Dalhoff K, Bendtsen F, et al. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. <i>Lancet</i>. 2002;360(9340):1151-1152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/12387966/pubmed\" target=\"_blank\" id=\"12387966\">12387966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seifert SA, Kirschner RI, Martin TG, Schrader RM, Karowski K, Anaradian PC. Acetaminophen concentrations prior to 4 hours of ingestion: impact on diagnostic decision-making and treatment. <i>Clin Toxicol (Phila)</i>. 2015;53(7):618-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/26107627/pubmed\" target=\"_blank\" id=\"26107627\">26107627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepel M, van der Giet M, Schwarzfeld C, et al, &ldquo;Prevention of Radiographic-Contrast-Agent-Induced Reductions in Renal Function by Acetylcysteine,&rdquo; <i>N Engl J Med</i>, 2000, 343(3):180-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/10900277/pubmed\" target=\"_blank\" id=\"10900277\">10900277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walls L, Baker CF, Sarkar S. Acetaminophen-induced hepatic failure with encephalopathy in a newborn. <i>J Perinatol</i>. 2007;27(2):133-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/17262050/pubmed\" target=\"_blank\" id=\"17262050\">17262050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walson PD and Groth JF Jr, &ldquo;Acetaminophen Hepatotoxicity After Prolonged Ingestion,&rdquo; <i>Pediatrics</i>, 1993, 91(5):1021-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/ 8474802 /pubmed\" target=\"_blank\" id=\" 8474802 \"> 8474802 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waring WS, Stephen AF, Robinson OD, et al,&ldquo;Lower Incidence of Anaphylactoid Reactions to N-Acetylcysteine in Patients With High Acetaminophen Concentrations After Overdose,&rdquo; <i>Clin Toxicol (Phila)</i>, 2008, 46(6):496-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/18584360/pubmed\" target=\"_blank\" id=\"18584360\">18584360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilkes JM, Clark LE, and Herrera JL, &quot;Acetaminophen Overdose in Pregnancy,&quot; <i>South Med J</i>, 2005, 98(11):1118-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-pediatric-drug-information/abstract-text/16351032/pubmed\" target=\"_blank\" id=\"16351032\">16351032</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13239 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056251\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F48879029\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056243\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130142\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130127\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056255\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F130161\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056254\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F130222\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130219\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130149\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130131\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298677\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130136\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130152\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056250\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130130\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F130148\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130151\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130153\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13239|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetylcysteine-drug-information\" class=\"drug drug_general\">Acetylcysteine: Drug information</a></li><li><a href=\"topic.htm?path=acetylcysteine-patient-drug-information\" class=\"drug drug_patient\">Acetylcysteine: Patient drug information</a></li></ul></div></div>","javascript":null}